RegMed Investors’ (RMi) closing bell analysis, the fear and greed indicator is up

December 15, 2016 5:31pm

As far as “our” universe is concerned, there's a difference between predicting what could, might or should happen … especially where 2017 is about to knock on the door.

Pre-open indication’s tally:  3 hits (BTX, BCLI and VCEL) and 2 miss (KITE and SGMO)

There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.

I answer one question; in which company should investors put, keep and commit their money!

I say today what others won't, so you can do what others can't!

U.S. stocks rose on Thursday as a post-election rally resumed, while investors digested a slew of economic data and the Federal Reserve's decision to raise interest rates.

The NASDAQ closed UP +20.18 or +0.37% to 5,456.85 and the DOW closed UP +59.71 or +0.30% to 19,852.24.

A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:   

• The open was negative with an A/DL of 13/26 and 4 flats;                     
• The mid-day jumped positive with an A/DL of 24/19 and 0 flat;
• The closing bell was stayed positive with A/DL of 23/19 and 1 flat;

Henry’omics:

The stem, cell, gene and regenerative therapy (SCG&RT) sector opened negative, flipped positive at the mid-day and closed positive.

• From this morning’s investor’s letter, “The market is what it is, but what will it be? While “our” universe “floats like a butterfly and stings like a bee”.  I’d be looking for 2016’s bottoms in “some” equities for a 2017’s BUY in.”

The iShares Russell 2000 (IWM) indicated a positive pre- open of +0.37% and closed UP +0.75%; the iShares NASDAQ Biotechnology (IBB) did NOT indicate in the pre-open and closed UP +0.94%.

The CBOE Volatility Index (VIX), widely considered the best gauge of fear in the market, traded near 12.7.

Out and about:

Biostage (BSTG) jumps +$0.12 or +14.12% to $0.97 on solid volume – 195.8 K <3 month average = 127.2 K shares> - Chia Pet …?

• Chia Pets are American styled terracotta figurines used to sprout chia, where the chia sprouts grow within a couple of weeks to resemble the animal's fur or hair. Moistened seeds of chia (Salvia hispanica) are applied to the grooved terra cotta figurine body.

MiMedx (MDXG) … Responded to the frivolous lawsuit filed against the Company by two former employees and the press release issued by these individuals…

Parker H. "Pete" Petit, Chairman and CEO, commented, "This process began with these individuals making allegations which I viewed as not factual and fallacious.  In accordance with our corporate policies, we submitted the allegations to our Board of Directors to thoroughly review the issues.  However, in the process of doing that investigation, we found out that these two individuals had been selling competitive products and other products for over a year into our accounts.  Therefore, earlier this week, their employment was terminated and lawsuits filed against them for their breach of their duty of loyalty and contractual obligations to the Company."

Today’s 3 biggest $ gainers included:

• Bluebird bio (BLUE) +$2.25;
• Kite Pharma (KITE) +$1.64 after Wednesday’s +$1.02;
• Juno Therapeutics (JUNO) +0.75

Today’s 3 biggest $ losers of the session were:

• Vericel (VCEL) -$0.60 after Wednesday’s +$1.50;
• Applied Genetic Technologies (AGTC) -$0.20;
• Capricor (CAPR) -$0.18

The downside trend reflects a pricing trend range of:

• Thursday’s decliners ranged from -0.11% <MDXG> to -15.06% <NWBO>in 19 equities;
• Wednesday’s decliners ranged from -0.22% <MDXG> to- 7.36% <IMUC> in 26 equities;
• Tuesday’s decliners ranged from -0.64% <CYTX> to -14.19% <ISCO> in 19 equities;
• Monday’s decliners ranged from -0.00% <BCLI> to -19.83% <OPXA> in 27 equities;

The upside shows a pricing trend range of:

• Thursday’s gainers ranged from +0.28% <VTGN> to +14.22% <BSTG>   in 22 equities;
• Wednesday’s gainers ranged from +0.08% <ONCE> to +57.69% <VCEL> in 16 equities
• Tuesday’s gainers ranged from +0.63% to +10.80% in 22 equities;
• Monday’s gainers ranged from +0.63% <CLLS> to +12.29% <CUR> in 14 equities;

Wrap-up: anybody can read a paragraph … review the percentage changes per day in the week of the decliners and advancers while …

• Monday’s 14 gainers compared to Tuesday’s 22 and was followed by Wednesday’s 16 and Thursday’s 23
• Monday’s 27 decliners compared to Tuesday’s 19 and was followed by Wednesday’s 26 and Thursday’s 19

Pre-open indication’s tally:  3 hits (BTX, BCLI and VCEL) and 2 miss (KITE and SGMO)

• BioTime (NYSEMKT: BTX) closed UP +$0.16 – hit;
• Brainstorm Cell Therapeutics (BCLI) closed DOWN -$0.14 – hit;
• Kite Pharma (KITE) closed UP +$1.64 – miss;
• Sangamo (SGMO) closed UP +$0.05 – miss;
• Vericel (VCEL) closed DOWN -$0.60 – hit;

Percentage (%) decliners:

• Northwest Bio (NWBO) -15.06% after Wednesday’s +21.17% after Tuesday’s +10.66% after Monday’s +3.17%;
• Vericel (VCEL) -14.63% after Wednesday’s +57.69%;
• Capricor (CAPR) -6.95%;
• Histogenics (HSGX) -6.40%;
• International Stem Cell (ISCO) -6.21% after Wednesday’s +9.02% after Tuesday’s -14.19% after Monday’s -7.74%;

Percentage (%) advancers:

• Biostage (BSTG) +14.12%;
• Opexa (OPXA) +10.13% after Wednesday’s -6.74% after Tuesday’s -6.12% after Monday’s -19.83%;
• Fibrocell (FCSC) +6.19% after Wednesday’s -7.32% after Tuesday’s -13%;
• Organovo (ONVO) +7.05%;
• BioTime (NYSEMKT: BTX) +4.69%

Flat:                                                                                                      

• Stemline (STML) at $11.35

Review my fear gauge or the CBOE Volatility Index (VIX):

·         Thursday traded near 12.7;

·         Wednesday traded near 13.4;

·         Tuesday traded near 12.7;

·         Monday traded near 12.64;

·         Friday traded near 11.8;

·         Last Thursday traded 12.64;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.